I'm LongbridgeAI, I can summarize articles.Boston Scientific gained 2.05% this week to close at $47.80, outpacing the S&P 500, which edged up 0.09%, by roughly 1.96 percentage points. The stock saw a run-up and pullback pattern: Monday (Aug 31) opened at $46.40 and reached an intraday high of $48.965 before settling at $48.30; Wednesday (Sep 2) touched the week’s high of $49.66, then slid through Thursday (Sep 3) to close near its weekly low at $46.95; Friday (Sep 4) rebounded to $47.80. Weekly amplitude was 7.69%.
The Week
Boston Scientific gained 2.05% this week to close at $47.80, outpacing the S&P 500, which edged up 0.09%, by roughly 1.96 percentage points. The stock saw a run-up and pullback pattern: Monday (Aug 31) opened at $46.40 and reached an intraday high of $48.965 before settling at $48.30; Wednesday (Sep 2) touched the week’s high of $49.66, then slid through Thursday (Sep 3) to close near its weekly low at $46.95; Friday (Sep 4) rebounded to $47.80. Weekly amplitude was 7.69%. Average daily volume was about 16.6m shares, roughly 11% below the recent median, so turnover was subdued. Spot remains below the 20-day moving average of $49.514 but above the 60-day line of $46.681.
Key Events
The main story at Boston Scientific this week centres on its spinal cord stimulator business. On Monday (Aug 31), Wisner Baum was named to the leadership team for federal spinal cord stimulator litigation. On Saturday (Sep 5), the company announced a recall of spinal cord stimulator leads over fracture risk. The two developments point to the same regulatory and product-safety theme. Elsewhere on Tuesday (Sep 1), the stock was reported to outperform peers among medical device names. On Wednesday (Sep 2) it drew unusually large options trading, while Midwest Professional Planners LTD. disclosed selling shares. Friday (Sep 4) brought a filing with limited headline detail. Overall, company-specific news converged on the stimulator litigation and recall, with intraday moves and a single institutional position change playing peripheral roles.
Analyst Ratings
As of Sep 4, 31 analysts cover Boston Scientific: 18 rate it buy, 8 rate it overweight and 5 rate it hold, with no underweight or sell ratings. The consensus rating is buy, and the consensus target sits at $62.69, roughly 31.15% above the last close of $47.80. Targets range from $44 to $94, a spread of about $50 that points to wide disagreement. Within the medical device industry, the stock ranks No. 2 among 142 names.
The Week Ahead
A batch of US macro data lands early next week: NFIB small business optimism on Tuesday (Sep 8), and jobless claims, PPI prints and a 10-year Treasury auction on Thursday (Sep 10). These will refresh the picture on rates and growth, which matters for a long-duration sector like medical devices. On the company side, the next earnings event is the fiscal Q3 2026 release on Oct 28 before the open, so no Boston Scientific earnings update is due next week.
In Short
Boston Scientific’s week is defined by competing signals. Most brokers rate it buy and the consensus target is more than 30% above spot, tilting the ratings picture upward. At the same time, the spinal cord stimulator litigation advance and lead recall push product risk back into focus. The latest session’s money flow shows large and medium orders as net sellers while small orders were net buyers, a split structure. At roughly 18.85x P/E and 2.78x book, valuations are not stretched. The question ahead is whether the recall widens in scope and whether next week’s macro data shifts rate expectations enough to weigh on growth-stock valuation.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.